Antibacterial Agents TRIZ Cases

Segmented Chlamydia antigens trigger protective Th1 immunity to resolve insufficient cellular response in vaccine development.

Macrocyclic compounds inhibit bacterial type 1 signal peptidase, addressing multidrug-resistant pathogen treatment challenges.

Radical SAM epimerase converts L-configured amino acids to D-forms, extending peptide half-life against protease degradation.

Mucoadhesive nanocarriers enhance udder retention of benzathine cloxacillin, reducing infection recurrence and milk contamination.

Phospholipid carriers maintain medication contact in the ear canal, resolving compliance issues caused by sticky adhesive formulations.

Moderate concentration aqueous ertapenem sodium crystallization prevents degradation while achieving high purity.

Controlled molecular weight oligomeric lactic acid releases lactic acid gradually to treat bacterial vaginosis recurrence.

Low-temperature cyanylation activates polysaccharides to form stable conjugates with carrier proteins, resolving autoimmune risks from group B similarity.

Supplementing culture media with GM-CSF expands alveolar macrophage populations while preserving phenotypic integrity and functional capabilities.

Mutated pepducins silence constitutive GPCR activity without agonist effects, resolving efficacy trade-offs in PAR1 and PAR2 targeting.

Inhaled bismuth-thiol aerosols penetrate cystic fibrosis biofilms, reducing microbial load while avoiding systemic antibiotic resistance.

Recombinant polypeptide antigens induce toxin-neutralizing antibodies while simplifying purification compared to natural toxins.

Engineered bacteriophages inhibit resistance genes and SOS responses, reducing antibiotic selection pressure while improving bacterial killing rates.

Segmented DVD-Ig chains resolve molecular heterogeneity and yield issues by enabling controlled assembly of distinct antigen-binding domains.

Composite OMV vaccines combine specific outer membrane proteins with vesicles to resolve the trade-off between broad strain coverage and autoimmunity risks.

Synthetic receptors anchor into plasma membranes using cholesterol derivatives, enabling universal delivery of therapeutic agents across diverse cell types.

A bromophenyl imidazole compound synthesized using pyridinium hydrogen sulfate as a green catalyst and solvent.

Stapled antimicrobial peptide sAMP1 targets Staphylococcus aureus and cancer cells through a C10 hydrocarbon staple structure.

A thermo-responsive polymer film releases topical compositions upon body heat contact.

Oral pharmaceutical composition combines vitamin C, zinc, and garlic to stimulate immune responses, reducing infection duration without antibiotic resistance.

A non-lytic bacteriophage delivers nucleic acids into bacterial cells to enable conjugation-based transmission.

Arginine buffers cefepime and tazobactam pH to 4.5-8, preventing phlebitis while maintaining antibacterial efficacy.

Adenylate kinase protein from Mycobacterium tuberculosis inhibits gram-negative bacterial proliferation through selective membrane disruption.

Houttuynia cordata extract mediates infection treatment to reduce drug resistance and side effects while enhancing immune defense.

Ultrasonic irradiation synthesizes a novel heterocyclic pyridine compound with potent antibacterial activity against resistant bacterial strains.

A defined bacterial composition treats gastrointestinal dysbiosis by providing a stable, consistent population that reduces infection recurrence.

A marine algal glycoprotein medicament treats tuberculosis through specific weight ratios and molecular weights.

An escalating topiramate dosing regimen manages obesity through controlled release formulations.

A roasted hop extract combines with xanthohumol to form a stable composite composition.

Bacteriocins from Pseudomonas chlororaphis replace antibiotics to control fish diseases without triggering resistance or causing tissue adhesions.

Flexible hydrophobic coatings prevent burst release from defects while maintaining stable drug delivery.

Composite human antibodies bind PD-L1 using CDR combinations from diverse human repertoires.

Podoviridae bacteriophage Bor-BRP-1 specifically infects and lyses Bordetella bronchiseptica bacteria.

Formula I compound from Streptomyces sp. fermentation treats resistant bacterial infections.

A substituted pyrrolidine derivative acts as a potent factor XIa inhibitor to deliver targeted anti-thrombotic activity.

Complexing agents like histidine improve corneal penetration, reducing dosing frequency and minimizing ocular irritation.

Human-originated EGF domain proteins bind lipopolysaccharides on bacterial cell walls to neutralize endotoxins.

A multivalent cattle vaccine combines modified live and inactivated antigens to induce robust cellular and humoral immune responses against multiple pathogens.

A multivalent antigen composition stimulates immune responses against seven field strains of intestinal pathogens in poultry.

Recombinant expression vectors produce NetE toxin proteins to resolve incomplete understanding of Type A Clostridium perfringens enteric diseases.

Fluorinated bicyclic dihydropyrimidinones resolve metabolic stability and systemic exposure trade-offs to enhance therapeutic efficacy.

Targeting aberrant MUC1 and MUC13 expression restores intestinal barrier integrity in gastrointestinal disorders.